In a recent interview at the SNMMI conference, Roger Lecomte, Ph.D., and Vincent Doyon discussed the advent of ultra-high resolution (UHR) brain positron emission tomography (PET), which reportedly offers double the spatial resolution of conventional PET and may facilitate earlier detection of Alzheimer’s disease and other conditions.
Emphasizing pixelated detectors and an isotropic spatial resolution upward of 1.25 mm, ultra-high resolution (UHR) brain positron emission tomography (PET) represents a significant advance that provides improved characterization and quantification of brain regions that could not be seen with whole-body PET, noted Roger Lecomte, Ph.D., during a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference.
“The spatial resolution is a factor of two better than HRRT (High Resolution Research Tomograph) and a factor of three better than any clinical scanners today. It’s a quantum leap in terms of spatial resolution,” said Dr. Lecomte, a professor of nuclear medicine and radiobiology at the University of Sherbrooke in Quebec, Canada. “To image the brain where you have small structures in the cortex, the brain stem and different regions of the brain, spatial resolution is very important to be able to detect the uptake of radiotracers in very tiny structures.”
One of the areas of improvement with UHR PET imaging was the enhanced visualization of the subfields of the hippocampus that can play a role in the progression of Alzheimer’s disease, according to Vincent Doyon, who presented some of the preliminary findings with UHR PET at the SNMMI conference.
“Depending on how these subfields are affected in the disease, we can see whether treatments are effective for the patient,” added Doyon, a master’s student in the Department of Radiation Sciences and Biomedical Imaging at the University of Sherbrooke.
Donyon added that UHR PET offers enhanced visualization of brainstem nuclei, including raphe nuclei, that may aid in the diagnosis and treatment of a variety of neuropsychiatric conditions, including schizophrenia, depression, and anxiety disorders.
For other insights from Dr. Lecomte and Mr. Doyon, watch the video below.
Study Examines Prognostic Value of 68Ga-PSMA-11 PET/CT for Patients at High Risk of PCa
June 21st 2024Initial detection of metastatic prostate cancer via 68Ga-PSMA-11 PET/CT was significantly associated with PSA values > 20 ng/ml, ISUP grade > 3 and MRI T-stage > 3, according to research presented recently at the SNMMI conference.
SNMMI: Can Ultra-Low Dose PET Supplant the Need for CT Attenuation Correction?
June 11th 2024Ultra-low dosing with long axial field-of-view positron emission tomography (PET) scanners facilitates qualitative PET imaging at a more than 50 percent reduction of conventional radiation dosing with PET, according to new research presented at the SNMMI 2024 conference.
SNMMI: AI May Enhance Detection and Risk Assessment for Multiple Cancers on Whole-Body PET/CT Scans
June 10th 2024Deep transfer learning may elevate the capability of whole-body PET/CT scans to diagnose multiple cancers, ranging from breast cancer and lung cancer to melanoma and prostate cancer, according to new research presented at the SNMMI conference.